PrIME Biologics Private Raises SGD16M in Equity Funding

PrIME Biologics Private Limited, a Singapore-based biotech company, raised SGD16M in equity funding.

Backers included Xeraya Capital via its affiliate, Pulau Manukan Ventures Labuan Ltd, and JP Asia Prime Capital Pte Ltd.

The company intends to use the funds to establish a human blood plasma fractionation plant in its Singapore cGMP facility which is expected to be registered with the Singapore Health Science Authority and fully operational in January 2015.

Led by Dr Hari Nair, PrIME Biologics Executive Chairman, PrIME Biologics has developed a disposable therapeutic plasma manufacturing process, which promises to increase product yields while increasing product safety and removing viruses, bacteria, endotoxins and prions.



Join the discussion